Patents Assigned to Universite Montpellier 2
-
Patent number: 9309275Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 3?-deoxy nucleoside compounds according to Formula 3001a or 3001b: or a pharmaceutically acceptable salts, solvates, stereoisomeric forms, tautomeric forms, or polymorphic forms thereof, wherein PD, Base1 and Base2 are as provided herein.Type: GrantFiled: March 3, 2014Date of Patent: April 12, 2016Assignees: IDENIX PHARMACEUTICALS LLC, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ MONTPELLIER 2 SCIENCES ET TECHNIQUESInventors: Alistair James Stewart, Adel M. Moussa, Benjamin Alexander Mayes, Francois-Rene Alexandre, Dominique Surleraux, Christophe Claude Parsy, Claire Pierra, David Dukhan, Gilles Gosselin
-
Patent number: 9296778Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.Type: GrantFiled: May 21, 2013Date of Patent: March 29, 2016Assignees: Idenix Pharmaceuticals, Inc., Centre National De La Recherche Scientifique, Universite Montpellier 2 Sciences Et TechniquesInventors: Christophe Claude Parsy, Francois-Rene Alexandre, Cyril B. Dousson, David Dukhan, Gilles Gosselin, Houcine Rahali, Dominique Surleraux
-
Patent number: 9274110Abstract: The present invention relates to a method for the in vitro diagnosis of active tuberculosis, comprising a step of contacting lymphocytes of a patient suspected to have active tuberculosis with at least one protein of mycobacteria, said protein being an enzyme having a lipolytic activity, and a step of detecting the presence of specific activated lymphocytes.Type: GrantFiled: June 1, 2012Date of Patent: March 1, 2016Assignees: Universite Montpellier 2 Sciences et Technique, Universite Montpellier 1, Centre Hospitalier Universitaire de Montpellier, Centre National de La Recherche ScientifiqueInventors: Edouard Tuaillon, Pierre-Alain Rubbo, Stephane Canaan, Laurent Kremer, Nicolas Nagot, Philippe Van De Perre, Jean-Pierre Vendrell
-
Patent number: 9233931Abstract: The present invention relates to a compound of one of the formulas I to XXI; a pharmaceutical composition comprising at least one such compound; and the use of at least one such compound in preparing a drug to treat, in a subject, a genetic disease resulting from at least one splicing anomaly.Type: GrantFiled: November 4, 2013Date of Patent: January 12, 2016Assignees: CENTRE NATIONALE DE RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE MONTPELLIER 2 SCIENCES ET TECHNIQUESInventors: Jamal Tazi, David Grierson, Florence Mahuteau-Betzer, Pierre Roux
-
Patent number: 9224463Abstract: A memory device includes at least one memory cell having a first transistor coupled between a first storage node and a first supply voltage; a second transistor coupled between a second storage node and the first supply voltage and a single resistance switching element. Control terminals of the first and second transistors are coupled to the second and first storage nodes respectively. The single resistive switching element is coupled in series with the first transistor and is programmable to have one of first and second resistances. The first storage node is coupled to a first access line via a third transistor connected to said first storage node, and the second storage node is coupled to a second access line via a fourth transistor connected to the second storage node.Type: GrantFiled: January 19, 2012Date of Patent: December 29, 2015Assignees: Centre National de la Recherche Scientifique, Université Montpellier 2Inventors: Yoann Guillemenet, Lionel Torres
-
Patent number: 9211300Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are according to Formula 1501: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein B, PD, RA, RB, RC, L, M and Z are as described herein.Type: GrantFiled: December 17, 2013Date of Patent: December 15, 2015Assignees: Idenix Pharmaceuticals LLC, Centre National De La Recherche Scientifique, Universite Montpellier 2 Sciences et TechniquesInventors: Benjamin Alexander Mayes, Adel M. Moussa, Alistair James Stewart, Gilles Gosselin
-
Publication number: 20150344552Abstract: Disclosed are specific antibodies against the protein Trio, their method of production, and their use in in vitro cancer prognostic method. Also described are the antigens enabling production of the antibodies.Type: ApplicationFiled: December 6, 2013Publication date: December 3, 2015Applicants: UNIVERSITE MONTPELLIER 2 SCIENCES ET TECHNIQUES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Anne DEBANT, Jerome BOUDEAU
-
Patent number: 9184585Abstract: The invention relates to a static converter connected between an electrical voltage source and an electrical load, said converter including a main static conversion arm comprising an output electronic switching cell and a backup conversion arm having identical structures. The static converter includes a pair of fuses connected on either side of the main arm, and a switching circuit comprising a connection element connecting the backup arm to the connection points between the fuses and the input terminals of the main arm, such that, when a fault occurs on one of the switching cells forming the main arm, a stable conductive link is established between the two fuses, the main arm is isolated by the two fuses, and the backup arm is spontaneously connected to the output of the main arm via the conductive line and replaces the main arm.Type: GrantFiled: June 24, 2011Date of Patent: November 10, 2015Assignees: Institut National Polytechnique de Toulouse, Universite de Toulouse II Le Mirail, Universite Montpellier 2, Sciences et Techniques, Centre National de la Recherche Scientifique (C.N.R.S.)Inventors: Jean-Jacques Huselstein, Emmanuel Sarraute, Frédéric Richardeau, Thierry Martire
-
Patent number: 9184459Abstract: The invention relates to a polymer comprising at least one polymeric chain of a first type, the said chain comprising at least two blocks, the same or different, the said blocks comprising repeat units derived from the polymerisation of styrene monomers, the said units comprising at least one phenyl pendant group carrying at least one —SO3R group, R possibly being a hydrogen atom, an alkyl group or cationic counter-ion, the said two blocks being separated by a spacer group, the spacer group is a perfluorocarbon group.Type: GrantFiled: September 21, 2011Date of Patent: November 10, 2015Assignees: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE MONTPELLIER 2, SCIENCES ET TECHNIQUES, ECOLE NATIONALE SUPERIEURE DE CHIMIE DE MONTPELLIERInventors: Pierrick Buvat, Jannick Bigarre, Renaud Perrin, Bruno Ameduri, Aurelien Soules, Bernard Boutevin
-
Patent number: 9175334Abstract: The invention relates to an in vitro method for identifying microRNAs or the target mRNAs thereof, the expression of which during the infection of cells by a virus using a cell receptor and at least one cell co-receptor for entering the cell, is specifically modified on the basis of the cell co-receptor used by the virus for its entering the cells, comprising: i) determining the microRNA expression levels in a test cell expressing a receptor, a first co-receptor and at least one other co-receptor, after infection by a first virus using the first co-receptor and by at least one other virus using another co-receptor, respectively; ii) identifying the microRNAs, the expression level of which is modulated during the infection by each of the viruses in relation to the expression level in the uninfected cells; iii) comparing the thus-identified microRNAs; iv) selecting the microRNAs, the modification of the expression level of which is specific to the use of a co-receptor; v) optionally identifying the target mRType: GrantFiled: September 1, 2010Date of Patent: November 3, 2015Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS, UNIVERSITE MONTPELLIER 2 SCIENCES ET TECHNIQUES, UNIVERSITE PARIS-DIDEROT-PARIS 7Inventors: Charles-Henri Lecellier, Valerie Courgnaud, Manuella Bouttier, Diane Descamps, Gilles Collin
-
Publication number: 20150307887Abstract: The present invention relates to FLT3 receptor antagonists or inhibitors of FLT3 receptor gene expression for the treatment or the prevention of pain disorders.Type: ApplicationFiled: July 8, 2015Publication date: October 29, 2015Applicants: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE MONTPELLIER 1, UNIVERSITE MONTPELLIER 2 SCEINCES ET TECHNIQUESInventor: Jean VALMIER
-
Patent number: 9157912Abstract: A method for the diagnosis and/or prognosis of inflammatory states, and the use of at least one soluble receptor-binding (RBD), for the identification and quantification of the expression of membrane receptors present on the surface of target granulocytes, said identification and quantification taking place at a given time or during a given time interval, and allowing the diagnosis and/or prognosis of inflammatory states in a mammal.Type: GrantFiled: September 19, 2011Date of Patent: October 13, 2015Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE MONTPELLIER 2 SCIENCES ET TECHNIQUES, STANFORD UNIVERSITYInventors: Rabindra Tirouvanziam, Julie Laval, Jean-Luc Battini, Marc Sitbon
-
Patent number: 9149796Abstract: The use of metal-accumulating plants for implementing chemical reactions.Type: GrantFiled: November 18, 2010Date of Patent: October 6, 2015Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE MONTPELLIER 2 SCIENCES ET TECHNIQUESInventors: Claude Grison, Jose Escarre
-
Patent number: 9127026Abstract: The present invention relates to a method for preparing a silica grafted with an organosilicon compound, to a grafted silica obtained according to said method and to the use thereof in compositions of silicone crosslinkable into an elastomer.Type: GrantFiled: August 16, 2012Date of Patent: September 8, 2015Assignees: BLUESTAR SILICONES FRANCE SAS, UNIVERSITE MONTPELLIER 2, SCIENCES ET TECHNIQUES, ECOLE NATIONALE SUPÉRIEURE DE CHIMIE DE MMONTPELLIER, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.)Inventors: David Mariot, François Ganachaud
-
Patent number: 9117521Abstract: The invention concerns a non-volatile memory element comprising: first and second transistors (106, 108) forming an inverter (104) coupled between a first storage node (112) and an output (110) of the memory element; a third transistor (116) coupled between the first storage node (112) and a first supply voltage (GND, VDD) and comprising a control terminal coupled to said output; a first resistance switching element (102) coupled in series with said third transistor and programmed to have one of first and second resistances (Rmin, Rmax) representing a non-volatile data bit; a fourth transistor (118) coupled between said storage node (112) a second supply voltage (VDD, GND); and control circuitry (130) adapted to activate said third transistor at the start of a transfer phase of said non-volatile data bit to said storage node, and to control said fourth transistor to couple said storage node to said second supply voltage during said transfer phase.Type: GrantFiled: June 14, 2012Date of Patent: August 25, 2015Assignees: Centre National de la Recherche Scientifique, Université Montpellier 2Inventors: Yoann Guillemenet, Lionel Torres
-
Publication number: 20150232489Abstract: The present invention concerns a funtionalisable polysilylated organosilane precursors with formula (I): in which: Z1 represents a moiety with formula (a) and Z2 represents a moiety with formula (b) Z1 and Z2 simultaneously represent a moiety chosen from the moieties R7R8Si(OH), R9Si(OH)2, Si(OH)3, R7R8SiO1/2, R9SiO or Si03/2; U represents a moiety chosen from the moieties with formulas (U1), (U2), (U3), (U4), (U5), (U6), (U7), (U8).Type: ApplicationFiled: July 8, 2013Publication date: August 20, 2015Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.), ECOLE NATIONALE SUPERIEURE DE CHIMIE DE DE MONTPEILLIER, UNIVERSITE MONTPELLIER 2, SCIENCES ET TECHNIQUESInventors: Michel Wong Chi Man, Xavier Cattoen, Nirmalya Moitra, Kristyna Burglova, Jana Hodacova
-
Patent number: 9109227Abstract: The present invention relates to FLT3 receptor antagonists or inhibitors of FLT3 receptor gene expression for the treatment or the prevention of pain disorders.Type: GrantFiled: January 5, 2011Date of Patent: August 18, 2015Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE MONTPELLIER 1, UNIVERSITE MONTPELLIER 2 SCIENCES ET TECHNIQUESInventor: Jean Valmier
-
Patent number: 9108908Abstract: The invention relates to a method for functionalizing natural fatty substances: According to said method, plant oils including at least two unsaturations and the derivatives thereof, fatty acids including at least one unsaturated compound and the derivatives thereof, and mixtures of same, are reacted with a thiol derivative of formula (I), at a temperature of between 0° C. and the temperature of total degradation of the natural fatty substance and in the presence of a thermal initiator compound or a redox initiator, or by UV radiation, or by UV radiation and in the presence of a photoinitiator. The invention also relates to the resulting functionalized fatty substances and to the use thereof for the preparation of polymers. The invention further relates to a method for preparing polymers from at least one functionalized fatty substance obtained by said functionalization method.Type: GrantFiled: June 30, 2011Date of Patent: August 18, 2015Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.), ECOLE NATIONALE SUPERIEURE DE CHIMIE DE MONTPELLIER, UNIVERSITE MONTPELLIER 2, SCIENCES ET TECHNIQUESInventors: Sylvain Caillol, Bernard Boutevin, Myriam Desroches
-
Patent number: 9108919Abstract: A method of preventing, inhibiting, or treating cancer that includes contacting a cell with at least one compound of formula (Ia) or a pharmaceutically acceptable salt thereof: where: R independently represents a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —CN group, a hydroxyl group, a —COOR1 group, a (C1-C3)fluoroalkyl group, a —NO2 group, a —NR1R2 group, or a (C1-C3)alkoxy group; R? is a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —NO2 group, a (C1-C3)alkoxy group, or a —NR1R2 group; and R1 and R2 are a hydrogen atom or a (C1-C3)alkyl group.Type: GrantFiled: November 22, 2013Date of Patent: August 18, 2015Assignees: ABIVAX, CENTRE NATIONALE DE RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE MONTPELLIER 2Inventors: Pierre Roux, Florence Mahuteau, Romain Najman, Jamal Tazi, Gilles Gadea, Didier Scherrer, Carsten Brock, Nathalie Cahuzac
-
Patent number: 9061999Abstract: The present invention relates to compound (I) for use as an agent for preventing, inhibiting or treating AIDS, wherein X is CR0 or N; R0, R1, R2, R3, R4, R7 and R8 independently represent a hydrogen atom, a halogen atom or a group chosen among a (C1-C5)alkyl group, a (C3-C6)cycloalkyl group, a (C1-C5)fluoroalkyl group, a (C1-C5)alkoxy group, a (C1-C5)fluoroalkoxy group, a —CN group, a —COORa group, a —NO2 group, a —NRaRb group, a —NRa—SO2—NRaRb group, a —NRa—SO2—Ra group, a —NRa—C(?O)—Ra group, a —NRa—C(?O)—NRaRb group, a —SO2—NRaRb group, a —SO3H group, a —OH group, a —O—SO2—ORc group, a —O—P(?O)—(ORc)(ORd) group, a —O—CH2—COORc group and can further be a group chosen among: R5 represents a hydrogen atom, a (C1-C5)alkyl group or a (C3-C6)cycloalkyl group; R10 is a hydrogen atom or a chlorine atom, and R11 is a hydrogen atom or a (C1-C4)alkyl group or anyone of its pharmaceutically acceptable salts.Type: GrantFiled: December 13, 2011Date of Patent: June 23, 2015Assignees: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE MONTPELLIER 2Inventors: Jamal Tazi, Florence Mahuteau, Romain Najman, Didier Scherrer, Noëlie Campos, Aude Garcel